Deal overview

Deal overview
Target TAKEDA PHARMACEUTICAL COMPANY LIMITED (XIIDRA RIGHTS)
Bidder NOVARTIS AG
Price £50.00 Full version or £25.00 Light version
Publication Date May 08, 2019
Abstract On 8 May 2019, the quoted Swiss pharmaceutical group Novartis AG ("Novartis") announced that it had entered into an agreement with Takeda Pharmaceutical Company Limited ("Takeda") to acquire the assets associated with the dry eye treatment Xiidra® worldwide. Takeda would receive US$ 3.4 billion upfront in cash and up to an additional US$ 1.9 billion in potential milestone ...
Number of pages (Full version) 5
Number of pages (Light version) 2
Format Adobe Acrobat (Download Acrobat Reader)
Free Sample Click Here to Download

Purchase this report

Accepted credit cards: Visa, America Express, Master Card

Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.

Search for Deals

Search over 70 million deal reports on more than 550,000 public and private companies. (copy)

Back to search results

Page Time: 0.033104s